fig1
Figure 1. P2Y12 inhibitor de-escalation in patients with ACS. Estimated risk of ischemic and bleeding events. While ischemic risk progressively weans off after the ACS, bleeding risk remains higher when patient is treated with dual antiplatelet therapy. ACS: Acute coronary syndrome.
